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Objective. To assess the ability of rheumatoid
arthritis (RA) fibroblast-like synoviocytes (FLS) to
function as antigen-presenting cells (APCs) for arthri-
togenic autoantigens found within inflamed joint
tissues.
Methods. Human class II major histocompatibil-
ity complex (MHC)–typed FLS were used as APCs for
murine class II MHC–restricted CD4 T cell hybridomas.
Interferon- (IFN)–treated, antigen-loaded FLS were
cocultured with T cell hybridomas specific for immuno-
dominant portions of human cartilage gp-39 (HC gp-39)
or human type II collagen (CII). T cell hybridoma
activation was measured by enzyme-linked immunosor-
bent assay of culture supernatants for interleukin-2.
Both synthetic peptide and synovial fluid (SF) were used
as sources of antigen. APC function in cocultures was
inhibited by using blocking antibodies to human class II
MHC, CD54, or CD58, or to murine CD4, CD11a, or
CD2.
Results. Human FLS could present peptides from
the autoantigens HC gp-39 and human CII to antigen-
specific MHC-restricted T cell hybridomas. This re-
sponse required pretreatment of FLS with IFN,
showed MHC restriction, and was dependent on human
class II MHC and murine CD4 for effective antigen
presentation. Furthermore, FLS were able to extract
and present antigens found within human SF to both
the HC gp-39 and human CII T cell hybridomas in an
IFN-dependent and MHC-restricted manner.
Conclusion. RA FLS can function as APCs and
are able to present peptides derived from autoantigens
found within joint tissues to activated T cells in vitro. In
the context of inflamed synovial tissues, FLS may be an
important and hitherto overlooked subset of APCs that
could contribute to autoreactive immune responses.
In contrast to the usual functions of fibroblasts,
fibroblast-like synoviocytes (FLS) have been hypothe-
sized to be important in joint inflammation and destruc-
tion (1–4). In rheumatoid arthritis (RA), FLS adopt an
inflammatory phenotype and secrete cytokines, pro-
teases, and other mediators. FLS secrete chemokines
that enhance leukocyte recruitment through synovial
endothelium (5). The most abundant infiltrating leuko-
cyte is the T lymphocyte, which may come into close
proximity to FLS, and interaction between these cells
could contribute to RA pathology. When FLS and T
cells are cocultured in vitro, activation of both cell types
is observed. FLS produce inflammatory mediators such
as interleukin-6 (IL-6), IL-8, and prostaglandin E2 (6),
and T cells up-regulate the activation markers CD69 and
CD25 (7). The functional consequences of these cocul-
tures mirror the molecular characteristics of RA syno-
vium, which suggests that similar interactions could be
occurring within the inflamed RA joint. These experi-
ments were performed without addition of antigen; thus,
the bidirectional activation observed was by mechanisms
independent of exogenous antigen presentation.
The etiology of RA is still unknown, although
several hypotheses have been proposed; however, a
strong genetic contribution to RA is well established.
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Within the Caucasian population, the most important
genetic association is with the major histocompatibility
complex (MHC) locus—specifically with HLA–DR4 and
other closely related DR alleles (8). One of the RA-
associated DR4 alleles, HLA–DRB1*0401, may also be
a predictor of disease severity, with homozygous indi-
viduals showing worse outcomes (9–12). The RA-
associated DR4 alleles all share a common motif near
the peptide binding groove at residues 70–74 of the
-chain (13–15). When human HLA–DRB1*0401 is
expressed as a transgene in mice, it confers susceptibility
to induction of arthritis by immunization with certain
autoantigens, even on otherwise genetically resistant
backgrounds (16).
Prior work has yielded mixed results regarding
the capacity of fibroblasts to function as true antigen-
presenting cells (APCs) for MHC-restricted responses
to exogenous antigens from pathogens (17–20). The
present study sought to evaluate the ability of FLS to
function as APCs for specific autoantigens present
within the joint and relevant to RA. Mouse T cell
hybridomas were employed that are specifically respon-
sive to arthritogenic peptides of human cartilage gp-39
(HC gp-39, YKL-40) or human type II collagen (CII)
presented by the human class II MHC allele HLA–
DRB1*0401, as measured by production of murine IL-2.
These hybridomas were developed from a mouse trans-
genic for the human class II allele HLA–DR4*0401.
Since these T cell hybridomas have been shown to
recognize their respective antigens when presented by
human dendritic cells or human monocytes that express
*0401 (21), they were used to evaluate the APC poten-
tial of FLS for arthritogenic autoantigens.
PATIENTS AND METHODS
Fibroblast isolation and culture. All procedures in-
volving specimens obtained from human subjects were per-
formed under protocols approved by the University of Michi-
gan Institutional Review Board. FLS were obtained by
collagenase (Worthington, Freehold, NJ) digestion of human
synovial tissue obtained at arthroplasty or synovectomy from
RA or osteoarthritic (OA) joints. The diagnosis of RA was
based upon the presence of at least 4 of the 7 American
College of Rheumatology (formerly, the American Rheuma-
tism Association) 1987 revised criteria (22). The diagnosis of
OA was based upon characteristic clinical and radiographic
features and was confirmed by pathologic findings at joint
surgery. Cells were maintained in CMRL medium (Invitrogen,
San Diego, CA) supplemented with 10% fetal calf serum (FCS;
Atlanta Biological, Atlanta, GA), 2 mM glutamine (Cambrex,
Walkersville, MD), 50 units/ml penicillin (Cambrex), and
50 g/ml streptomycin (Cambrex). FLS were used after pas-
sage 4 from primary cultures.
T cell hybridoma generation and culture. T cell hy-
bridomas specific for a 13-amino-acid peptide of the arthri-
togenic HC gp-39 (263–275) and a 15-amino-acid peptide
from human CII proteins (259–273) were developed and
characterized as previously described (21). T cell hybrid-
omas were cultured in RPMI 1640 medium (Invitrogen)
supplemented with 10% FCS, 2 mM glutamine, 50 units/ml
penicillin, 50 g/ml streptomycin, 0.6 mM sodium pyruvate
(Cambrex), 1 mM HEPES (Cambrex), and 0.055 mM
-mercaptoethanol (Invitrogen).
Antigens. Peptide antigens RSFTLASSETGVG and
GIAGFKGEQGPKGEP, corresponding to HC gp-39 263–275
and human CII 259–273, respectively, were synthesized by the
University of Michigan Protein Core. Synovial fluid (SF) was
obtained at therapeutic arthrocentesis, centrifuged to remove
cells, and stored at 80°C for subsequent use. For testing of
responses to SF antigens, FLS were loaded with 50%/50%
SF/medium (for the HC gp-39) or with 20%/80% SF/medium
(for the human CII hybridoma) as an antigen source. FLS were
incubated with antigens for 3–7 days before addition of T cell
hybridomas. Antigen incubation times 3 days resulted in
suboptimal antigen presentation.
FLS and T cell hybridoma coculture. FLS were cul-
tured with CMRL medium in 24-well plates at 10,000/well and
were allowed to adhere for 48 hours. FLS were then stimulated
with 1,000 units/ml interferon- (IFN) for an additional 48
hours to reinduce class II MHC, which is expressed in vivo by
FLS. Four days after initial plating, the medium was changed,
and new medium containing 1,000 units/ml of IFN and 10
g/ml of peptide antigen (HC gp-39 or human CII) was added
for another 3 days. Seven days after initial plating, the medium
was changed to T cell hybridoma medium, containing HC
gp-39 or human CII peptide at 10 g/ml. T hybridoma cells
(200,000) were added while maintaining antigen concentration
at 10 g/ml. T cells and FLS were allowed to interact for 3 days
before plates were frozen and thawed. Plates were spun down,
and supernatants were harvested.
Mouse IL-2 enzyme-linked immunosorbent assay
(ELISA). ELISAs were performed using OptEIA Mouse IL-2
kits (BD Biosciences, San Jose, CA). The manufacturer’s
protocols were followed.
MHC typing. DNA was isolated with the DNeasy
Tissue Kit (Qiagen, Chatsworth, CA). MHC analysis used the
HLA–DR Typing Tray and DR 4T SSP Unitray (both from
Pel-Freez, Rogers, AR) to identify the presence of a DR4
allele and the subtype of DR4, respectively. The manufactur-
er’s protocols were observed.
Blocking antibodies. For blocking assays, T cell hybrid-
omas were incubated, before being cocultured with FLS, in
medium containing 10 g/ml anti-CD4, anti-CD11a, anti-CD2,
or rat IgG. FLS were exposed to medium containing 10 g/ml
anti–class II MHC, anti-CD54, anti-CD58, or mouse IgG
before the addition of T cell hybridomas. When cells were
cocultured, additional antibodies were added to maintain a
final antibody concentration of 10 g/ml.
HC gp-39 ELISA. ELISA for HC gp-39 was performed
using a YKL-40 ELISA Kit (Quidel, San Diego, CA). The
manufacturer’s protocols were followed.
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RESULTS
Ability of FLS to present HC gp-39 and human
CII peptides. To assess the APC function of FLS,
these cells were treated with IFN, loaded with im-
munodominant peptides from HC gp-39 or human
CII, and cocultured with the HC gp-39– or human
CII–specific T cell hybridoma. For a control, the
peptide and T cell hybridoma pairs were mismatched
(FLS  HC gp-39 peptide  human CII hybridoma,
or FLS  human CII peptide  HC gp-39 hybrid-
oma). These mismatched peptide pairs are subse-
quently referred to as irrelevant peptide controls. The
supernatants from these cocultures were evaluated for
murine IL-2 as a measure of T cell stimulation due to
FLS presentation of peptide antigen. FLS cocultured
with the HC gp-39– or human CII–specific T cell
hybridoma cells along with the cognate peptide in-
duced significant release of IL-2 from the hybridomas
(Figure 1A). When irrelevant peptide was presented,
IL-2 production was greatly reduced. Hybridomas
cultured with cognate peptide in the absence of FLS
produced very little or no IL-2, indicating the require-
ment for an APC.
To explore the effects of antigen concentration
on the ability of FLS to activate T cell hybridomas, FLS
were loaded with various concentrations of peptide
antigen, ranging from 0.1 g/ml to 10 g/ml, and used as
APCs for T cell hybridomas. IL-2 production by the T
cell hybridomas increased with the antigen concentra-
tion (Figure 1B).
Figure 1. Presentation of arthritogenic peptides to T cell hybridomas by fibroblast-like synoviocytes (FLS). A, FLS were plated and treated with
interferon- (IFN). Human cartilage gp-39 (HC gp-39) or human type II collagen (HcII) peptides were pulsed onto FLS before they were
cocultured with T cell hybridomas. Mouse interleukin-2 (mIL-2) in culture supernatants from HC gp-39– or human type II collagen–specific T cell
hybridomas was measured by enzyme-linked immunosorbent assay. Values are the mean from 1 experiment representative of a total of 5
experiments. Error bars represent the range of the 95% confidence intervals. B, FLS were pulsed with decreasing concentrations of HC gp-39 peptide
before coculture with the HC gp-39–specific hybridoma. Values are the mean from 1 experiment representative of a total of 2 experiments. Error
bars represent the range of the 95% confidence intervals. C, FLS received medium either containing or devoid of IFN before being pulsed with
peptide and cultured with the HC gp-39–specific hybridoma. Values are the mean from 1 experiment representative of a total of 5 experiments. Error
bars represent the range of the 95% confidence intervals.
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Dependence on IFN of FLS APC function. We
assessed the requirement of IFN pretreatment for
effective APC function by FLS. FLS, with or without
IFN pretreatment, were cultured in medium containing
HC gp-39 peptide antigen and used as APCs for the HC
gp-39 T cell hybridoma (Figure 1C). IFN pretreatment
was necessary to reinduce expression of class II MHC
found in vivo on these FLS, which had been passaged in
vitro. IFN-treated FLS were able to present antigen to
T cell hybridomas, but FLS cultured without IFN did
not function as APCs. The IFN dependence of FLS
APC function is consistent with class II MHC–
dependent antigen presentation and recognition.
Class II MHC restriction of fibroblast APC func-
tion. Not all FLS lines were able to function as APCs,
even with IFN stimulation. It was hypothesized that
lack of APC function by FLS was due to the MHC
restriction of the T cell hybridoma response. Chromo-
somal DNA from various FLS lines, as well as from
fibroblast lines from other tissue sources, were harvested
and screened for HLA type by polymerase chain reac-
tion. Using HLA–DRB1*0401–positive and DR4-
negative FLS lines as APCs for peptide antigens, we
found that only *0401-positive cell lines could present
antigen to the HC gp-39 T cell hybridoma (Figure 2A).
When a DR4-negative cell line was used as an APC, no
IL-2 was produced by the T cell hybridoma.
We next sought to assess the DR4 subtype spec-
ificity of antigen presentation and also the antigen
presentation potential of fibroblasts other than FLS. To
address these issues, MHC-typed lung fibroblasts cul-
tured from interstitial pneumonia biopsy samples were
treated with IFN, loaded with cognate antigen or
irrelevant antigen, and used as APCs. Similar to FLS,
lung fibroblasts were able to load peptide antigen and
present it to the HC gp-39 T cell hybridoma (Figure 2B).
Comparing *0401-positive, *0404-positive, and DR4-
negative lung fibroblast lines, this system showed strin-
gent specificity for antigen recognition only in the
context of *0401. Even the *0404 allele, which also
contains the shared epitope and is associated with RA,
did not function as an effective activation signal for the
T cell hybridoma. The ability of fibroblasts to function as
APCs is therefore not unique to fibroblasts from a
synovial source, and antigen presentation by fibroblasts
of any tissue follows strict MHC restriction.
Table 1 summarizes the results of HLA–DR
typing of fibroblasts from various tissue sources and
assessment of APC function of the fibroblasts used as
APCs for the HC gp-39 T cell hybridoma. The ability of
fibroblasts to act as APCs corresponds strictly to posses-
sion of the correct class II MHC subtype, specifically
HLA–DRB1*0401, irrespective of the tissue source.
Notably, DRB1*0403- and *0404-expressing fibroblasts
did not function as APCs for the HC gp-39 T cell
hybridoma. Similar to professional APCs, fibroblast
APCs must express the class II MHC allele with which T
cells were educated.
Figure 2. Major histocompatibility complex restriction of antigen presentation by FLS and lung fibroblasts. A, HLA–DRB1*0401–positive and
–negative FLS lines were used to present peptide antigen to an HC gp-39 T cell hybridoma. Values are the mean from 1 experiment representative
of a total of 3 experiments. Error bars represent the range of the 95% confidence intervals. B, Arthritogenic peptide antigen presentation by
fibroblasts is restricted to HLA–DRB1*0401. Lung fibroblasts expressing the rheumatoid arthritis–associated DR4 subtype alleles *0401 or *0404
were pulsed with HC gp-39 peptide and cocultured with the HC gp-39 T cell hybridoma. IL-2 was measured in supernatants by enzyme-linked
immunosorbent assay. Values are the mean from 1 experiment representative of a total of 3 experiments performed in duplicate. Error bars
represent the range of the 95% confidence interval. See Figure 1 for definitions.
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Dependence of APC function on class II MHC
and CD4. Given that IFN is required to achieve
effective APC function of FLS, and given that class II
MHC restriction is displayed by T cell hybridomas, the
roles of class II MHC and other structures important to
T cell activation were further evaluated. IFN stimula-
tion up-regulates many proteins important for antigen
presentation. We sought to isolate those critical to
FLS–T cell interactions. Blocking antibodies were added
to cocultures of antigen-loaded FLS and T cell hybrid-
omas, including human class II MHC, CD54, and CD58
on the FLS surface and murine CD4, CD2, and CD11a
on the T cell surface. Blockade of human class II MHC
or murine CD4 by antibody abolished the FLS activation
of the HC gp-39 T cell hybridoma (Figure 3), and thus
further demonstrated the importance of a functional
peptide–MHC complex. Interference with human CD54
adhesion yielded less robust effects, and blockade of
murine CD11a did not cause a similar reduction in IL-2
production. Thus, it is unclear at this time whether a
CD54–CD11a interaction is required for FLS to present
antigen to T cell hybridomas. A CD58–CD2 interaction
also does not seem to be required for FLS APC function
in this system.
Ability of FLS to present autoantigens from SF.
To use a source of antigen more biologically relevant
than synthetic peptides, human SF from RA and OA
patients was added to cultures of FLS. SF was collected
from patients undergoing therapeutic arthrocentesis.
Collected SF was centrifuged at 2,000 revolutions per
minute for 30 minutes to pellet synovial cells. The
supernatant was used as an antigen source after being
diluted to 20% in medium. FLS were able to extract
human CII antigens from some SF and activate the
human CII T cell hybridoma (Figure 4A). One SF
sample was able to elicit IL-2 responses that were
comparable with 10 g/ml of peptide antigen (RA SF8).
Other SF samples (RA SF6 and OA SF3) were pre-
sented by FLS, but were not as potent as 10 g/ml of
peptide antigen. FLS were unable to present antigen
from some SF samples. None of the SF samples tested
activated the human CII hybridoma in the absence of
FLS; however, 1 SF sample did activate the HC gp-39
hybridoma minimally (data not shown).
To assess whether the variability in the ability of
different SF samples to function as a source of antigen
reflected the antigen concentration present within the
fluid, various SF samples were presented to the HC
gp-39 T cell hybridoma by FLS. The HC gp-39 content
within these SF samples was measured by ELISA, and
these SF samples were then loaded onto FLS for antigen
presentation. The HC gp-39 concentration was lower in
SF than the amount of peptide used for antigen presen-
tation. SF HC gp-39 concentrations ranged from 1.19
g/ml to 3.10 g/ml (Figure 4B). FLS were able to
extract HC gp-39 from some SF samples and activate T
cell hybridomas (Figure 4B). Functional HC gp-39 anti-
gen was present in both RA and OA SF, similar to
human CII antigen, as indicated by induction of IL-2.
However, not all SF samples allowed FLS to activate
hybridomas, even when HC gp-39 antigen was detect-
Figure 3. Class II major histocompatibility complex (MHC II) and
CD4 dependency of the antigen-presenting cell function of FLS for
peptide antigen responses of T cell hybridomas. Blocking antibodies to
cell surface structures were added to cocultures of FLS and the HC
gp-39 T cell hybridoma. Mouse IL-2 was measured by enzyme-linked
immunosorbent assay. Values are the mean from 1 experiment repre-
sentative of a total of 2 experiments performed in duplicate. Error bars
represent the range of the 95% confidence intervals. MsIgG  mouse
IgG; RIgG  rat IgG (see Figure 1 for other definitions).
Table 1. Results of HLA–DR typing of fibroblasts from various
tissue sources and assessment of APC function of the fibroblasts used
as APCs for the human cartilage gp-39 T cell hybridoma*
Cell type,
cell line DR4 subtype APC function
Synovial
04M098 *0401 
04F115 *0401 
RWS *0401 
CLC *0401 
04F096 *0401 
RA35 None 
RA77 None 
Lung
100B *0401 
89A *0404 
103B None 
Skin
R1652 *0403 
* APC  antigen-presenting cell.
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able by ELISA at concentrations similar to those in
functionally presentable SF samples. One SF sample
activated the HC gp-39 hybridoma in the absence of FLS
and was excluded (data not shown).
Given the variability of antigen presentation us-
ing SF, we sought to ensure that antigen presentation
under these conditions required class II MHC expres-
sion, restriction, and dependence. To assess the require-
ment for class II MHC expression and restriction, one
*0401-negative and two *0401-positive FLS lines were
used to present SF to the human CII hybridoma. In a
parallel experiment, the *0401-positive FLS lines were
not prestimulated with IFN (Figure 4C). The same SF
sample was used for all conditions. In the absence of
IFN stimulation, neither *0401-positive FLS line pre-
sented antigens from SF to the T cell hybridoma, and
only basal levels of IL-2 were detectable. After IFN
stimulation, the *0401-positive FLS lines were able to
present antigen derived from SF to the human CII
hybridoma. The *0401-negative FLS line was unable to
Figure 4. Ability of FLS to extract antigen from synovial fluid (SF) and present it to HC gp-39 and human type II collagen (human CII) T cell
hybridomas. A, SF samples from rheumatoid arthritis (RA) and osteoarthritis (OA) patients were diluted to 20% in medium and loaded onto FLS
before coculture with the human CII–specific T cell hybridoma. B, FLS were loaded with RA or OA SF samples diluted to 50% in medium before
coculture with the HC gp-39–specific T cell hybridoma. The HC gp-39 concentration within the SF was measured by enzyme-linked immunosorbent
assay and is indicated below the x-axis. C, SF was diluted to 20% in medium and loaded onto FLS before coculture with human CII–specific T cell
hybridomas. Two *0401-positive FLS lines and one *0401-negative FLS line were used as antigen-presenting cells; the *0401-positive FLS lines were
cultured with or without IFN. D, Two different SF samples were loaded onto FLS before coculture with the human CII–specific T cell hybridoma.
Antigen presentation was inhibited by 10 g/ml of mouse anti-human class II major histocompatibility complex (anti-MHCII). Control antibody was
mouse immunoglobulin (MsIg). Values in A–D represent the mean. Error bars in A–D represent the range of the 95% confidence intervals. E, OA
or RA SF was loaded onto FLS and presented to the HC gp-39 T cell hybridoma. The resultant IL-2 production was represented as a percentage
of the IL-2 produced from 10 g/ml of HC gp-39 peptide and plotted on the y-axis. The x-axis displays the concentration of the HC gp-39 antigen
contained within SF. Linear regression analysis yielded an r2 value of 0.0677. See Figure 1 for other definitions.
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present SF antigens to the T cell hybridoma even after
IFN stimulation, and only basal levels of IL-2 were
detectable (similar to no IFN treatment) from these
cultures. IFN dependence and class II MHC restriction
provide strong evidence that antigen presentation of SF
by FLS is MHC dependent. To further prove the class II
MHC dependence of SF presentation, we employed
class II MHC blocking studies. Using 2 different SF
samples as antigen sources for FLS (Figure 4D), anti-
body to class II MHC specifically inhibited effective
APC function by FLS for both SF samples.
The lack of correlation between antigen concen-
tration in SF and the level of IL-2 produced by the HC
gp-39 T cell hybridoma contrasted with previous results
(Figure 1B), which showed that the level of IL-2 pro-
duced by T cell hybridomas correlated with the concen-
tration of peptide antigen presented. To explore this
discrepancy, we pooled the data from several experi-
ments that measured the antigen concentration of SF
and the ability of FLS to present HC gp-39 from SF to
the HC gp-39 hybridoma. For an internal control, the
resultant IL-2 response from these experiments was
normalized as a percentage of the IL-2 response elicited
by loading the same FLS lines with 10 g/ml of synthetic
peptide. This normalized response was plotted against
the HC gp-39 concentration in the SF as measured by
ELISA. A close correlation between the HC gp-39
concentration in SF and the amount of IL-2 produced by
the HC gp-39–specific T cell hybridoma was not ob-
served (Figure 4E). Curve fitting analysis yielded a very
low r2 value of 0.0677. We further evaluated some SF
samples that were not presentable by FLS, by adding 10
g/ml of HC gp-39 to the fluids before coculture with
the HC gp-39 T cell hybridoma. These SF samples
exerted an inhibitory effect on peptide antigen presen-
tation (data not shown). This result implies that in
addition to the presence of specific antigen, other as-
yet-uncharacterized factors in some SF samples regulate
the capacity of FLS to function as APCs.
DISCUSSION
Presentation of autoantigens to T cells in synovial
tissue could be very important in the initiation and
perpetuation of inflammatory arthritis. The RA-
associated MHC alleles possess a common sequence
motif referred to as the “shared epitope” (13). Structural
analysis of the shared epitope region shows that it is
positioned near the MHC peptide binding groove (15);
thus, it influences bound peptides or affects interactions
with T cell receptors (TCRs) (14). This suggests that
antigen presentation may be an important pathogenic
mechanism in RA.
Prior work has documented T cell–FLS interac-
tion leading to activation of both cell types (6,7,23), but
previous data regarding fibroblasts as APCs have been
mixed. Investigators in early studies using dermal fibro-
blasts observed that they were poor generators of allo-
geneic responses (17). This defect was not due to
inadequate expression of class II MHC, but rather to the
lack of an accessory molecule that could be provided by
conventional APCs. However, it was noted that dermal
fibroblasts could stimulate previously activated alloreac-
tive T cells. Expanding on this work, the capacity of
dermal fibroblasts to function in antigen presentation
was evaluated. Dermal fibroblasts were able to process
exogenous antigen, but did not function well as APCs
without accessory cell help (18,24). In both of those
studies, IFN was used to induce class II MHC, but
human autoantigens were not evaluated. These previous
studies do document fibroblast expression of functional
class II MHC.
FLS of RA synovium express high levels of class
II MHC in vivo and ex vivo (25), suggesting that the
potential exists for antigen presentation by FLS in RA.
Previous work indicated that FLS can process and
present bacterial antigens to T cell clones via a class II
MHC–restricted mechanism (19). FLS can also present
bacterial superantigens to polyclonal peripheral blood
lymphocytes, activating a significant subset of T cells.
However, these reports focus on exogenous antigens
from pathogens. Our current study has documented the
ability of FLS to function as APCs for human autoanti-
genic peptides and endogenous human proteins present
in SF, indicating that these interactions could be occur-
ring in vivo within an inflamed joint, in the absence of
infection.
There is also evidence that under some condi-
tions FLS might not activate T cells, but instead induce
anergy, in experiments that assessed the APC and
allostimulatory functions of FLS (26). In these studies,
FLS were able to load antigen onto class II MHC, but
allogeneic responses depended upon the addition of
accessory cells expressing CD80, and blockade of CD80
abolished the response (i.e., FLS are poor allogeneic
stimulators, similar to dermal fibroblasts [17]). When
FLS without accessory cells were cultured with T cells,
the T cells adopted a phenotype resembling anergy,
characterized by up-regulation of CD25, reduced prolif-
eration, and reconstitution of proliferation by exogenous
IL-2. This result implies that FLS cause anergy due to a
lack of costimulatory molecules, but that bystander cells
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expressing costimulatory molecules could overcome this.
The potential for accessory costimulation exists abun-
dantly within RA synovium due to the close proximity of
FLS to B cells, macrophages, and dendritic cells, as well
as other T cells.
The evidence that FLS can express functional
class II MHC is strong, but the function of FLS MHC
expression has not been thoroughly explored. Work in
transgenic mice suggests that the specific class II MHC
allele subtype has a striking effect on T cell polarization.
Evaluation of the T cells from DR4-transgenic mice
reveals functional differences between RA-associated
and non–RA-associated alleles. T cells from *0401-
transgenic mice, possessing the RA-associated allele,
differ from T cells from *0402-transgenic mice, which
carry a non–RA-associated allele, by their cytokine
profile after antigen stimulation. Mice transgenic for
*0401 show a skew toward a Th1-mediated immune
response and make greater levels of IFN and tumor
necrosis factor  (TNF) after stimulation with antigen
compared with *0402-transgenic mice (20).
A possible reason for differing T cell responses to
antigens presented by different DR4 alleles is that the
peptide binding repertoire of RA-associated DR4 alleles
is distinct from that of other DR4 alleles. HLA–
DRB1*0401 presents immunodominant peptides from
the autoantigens HC gp-39 and human CII, which are
peptides distinct from those presented by non-RA DR4
alleles (20). Perhaps the presentation of a unique panel
of peptides by RA-associated MHC activates a distinct
set of T cells in the periphery and educates a corre-
sponding set of T cells in the thymus, thus producing the
predisposition to autoimmunity (27,28).
Even though a definitive autoantigen (or autoan-
tigens) has yet to be consistently identified in this
process of T cell development and activation in RA, HC
gp-39 and human CII are plausible candidates. These
autoantigens are found within cartilage and synovial
tissues and are arthritogenic, able to induce inflamma-
tory arthritis in susceptible strains of rodents (29). HC
gp-39 is made by chondrocytes and macrophages, 2 cell
types that are found in RA joints. Elevated serum levels
of HC gp-39 appear to correlate with increased RA
disease activity (30–32). Peripheral blood mononuclear
cells from RA patients show an increased proliferative
response to HC gp-39 antigen compared with those from
healthy controls (33). The prevalence of HC gp-39–
responsive T cells in peripheral blood of RA patients
was similar to that seen in controls in 1 study (34), but
RA T cells produced increased IFN in response to HC
gp-39, whereas controls showed an IL-10 response,
indicating that there is a skew toward inflammation in
RA patients, while controls show a regulatory response
(35). Histologic studies have even identified HC gp-39
complexed with HLA–DRB1*0401 on APCs within hu-
man RA synovial tissue sections (36). These observa-
tions support the idea that HC gp-39–responsive T cell
clones might contribute to RA pathogenesis or joint
inflammation.
Like HC gp-39, human CII is a human autoanti-
gen, also used to induce arthritis in mice as a model of
RA (37). It is only found within cartilage and synovial
fluid or tissue. Although autoantibodies to human CII
and human CII–responsive T cell clones are not specific
for RA (38), T cell clones in RA patients have been
identified that have a TCR repertoire similar to that of
human CII–expanded T cells (39). There is also evi-
dence that T cell responses to altered forms of CII are
important in RA (40). Furthermore, cocultures of hu-
man CII–reactive T cells with FLS increased the produc-
tion of IFN, IL-17, TNF, IL-15, and IL-18 (23). These
studies suggest that T cell responses are altered in RA
patients such that responses to antigens might be skewed
toward a proinflammatory response centered around
HC gp-39 and/or human CII antigens, even when mea-
surable T cell proliferative responses are not remarkably
elevated.
In the current study, HLA–DRB1*0401–positive
fibroblasts from different tissue sources were able to
present immunodominant peptides from the arthrito-
genic proteins HC gp-39 and human CII to antigen-
specific T cell hybridomas. The key requirement appears
to be the expression of the correct class II MHC allele.
Since T cell hybridomas represent previously activated T
cells, minimal costimulation may be needed for reacti-
vation. Nonetheless, any activation of the T cell hybrid-
oma indicates that a functional peptide–class II MHC
complex is present on the FLS. If irrelevant peptide or a
class II MHC mismatch is present, no T cell stimulation
occurs. The significance of other structural interactions
outside of MHC–TCR is not yet clear. The CD54–
CD11a and CD58–CD2 interactions are often important
for professional APC interaction with T cells. Inhibiting
these interactions did not substantially disrupt FLS APC
function. Perhaps cross-species limitations of some co-
stimulatory receptor–ligand interactions and the relative
lack of dependence of hybridomas on costimulatory
signals minimize the roles of these molecules in the
system that we used.
FLS are also able to extract antigens from SF and
present the antigens to both HC gp-39 and human CII T
cell hybridomas. The exact nature of the antigenic
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material in SF is still unknown. It may include predi-
gested peptide fragments and/or intact proteins, such as
HC gp-39. Whether these antigens are passively loaded
onto FLS or are ingested and processed by FLS remains
to be discovered, and it is possible that both processes
can occur. In the current experiments, it was important
to exclude possible mechanisms of T cell–FLS interac-
tion that did not involve antigen presentation, and to
prove that FLS induction of the IL-2 by T cell hybrid-
omas was through antigen presentation. Thus, activation
of T cell hybridomas by FLS, as measured by IL-2,
showed MHC restriction, was antigen specific, required
IFN, and was dependent on functional class II MHC.
Moreover, SF from patients with RA or OA almost
never induced secretion of IL-2 by hybridomas in the
absence of FLS.
In the present study, we did not find a correlation
between the concentration of HC gp-39 in SF and the
ability of FLS to present antigens to the HC gp-39 T cell
hybridoma. The specificity of the HC gp-39 ELISA
regarding which region of the protein is recognized by
antibodies is unknown; the recognized portion could be
inconsequential to antigen presentation. Moreover, it is
possible that there are HC gp-39 degradation products
present in SF that were not recognized by the HC gp-39
ELISA. These fragmented portions of HC gp-39 could
result in a “functionally” high concentration of HC
gp-39, while leaving the measurable HC gp-39 low.
Conversely, the measurable HC gp-39 could be in rela-
tive abundance, while the portions responsible for anti-
gen presentation are reduced, leading to high measured
concentrations of HC gp-39 with little stimulatory ef-
fects on the hybridoma.
In addition to uncertain protein concentration,
SF also contains many factors that could affect antigen
presentation, enhancing or inhibiting it. Inflammatory
and inhibitory cytokines (e.g., IL-1 and IL-10) are
present in SF and may affect immune cell function.
Failure of FLS to present recombinant peptides in the
presence of certain SF samples supports the concept of
inhibitory factors within those SF samples (data not
shown). It is also notable that while professional APCs
can effectively present HC gp-39 and human CII anti-
gens with overnight incubation with antigen and 20-hour
coculture times with T cells, the kinetics are different for
FLS as APCs. FLS require prolonged incubation with
antigen and longer coculture times with T cells. This
suggests that FLS might not process and/or present
antigen as efficiently as their professional counterparts,
or that they might use entirely different mechanisms to
achieve the same ends. Given the chronicity of RA, the
prolonged time needed for FLS–T cell interactions
would not be an obstacle to the occurrence of such
interactions in vivo. These issues will require further
analysis in order to identify additional factors that
govern FLS APC function in vitro and in vivo.
FLS exist under unique conditions that provide
mechanisms for stimulation of T cells specific to arthri-
togenic autoantigens. FLS express high levels of class II
MHC in RA synovium and are chronically exposed to
autoantigens present within SF. Our studies indicate
that FLS can express a functional autoantigen–class II
MHC complex. In the context of an inflamed RA joint,
FLS could take up antigen, display antigenic peptides on
MHC, and activate T cells in an antigen-dependent
mechanism as suggested by findings of our in vitro
studies. However, the data in this report do not establish
that FLS can take up and process antigens with the same
efficiency as professional APCs. Nevertheless, the role
of nonclassic APCs (such as fibroblasts) as participants
in autoimmunity deserves further consideration.
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